SELLAS Life Sciences Group, Inc. (SLS) Declines to All-Time Low at $3.24

June 29, 2018 - By Ashley Edward

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) reached all time low on Jun, 29 touching $3.24. Our target is $3.08. It was reported by The company has $21.56M market cap. At $3.08 stock target, the company valuation changes by $1.08 million less.

SLS touched $3.24 during the last trading session after $0.29 change.Currently SELLAS Life Sciences Group, Inc. is downtrending after 71.31% change in last June 29, 2017. SLS has also 137,647 shares volume. SLS underperformed the S&P 500 by 83.88%.

For more SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) news brought out briefly go to:,,, or The titles are as follows: “SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVaxâ„¢ (nelipepimut-S) Study in Combination with …” brought out on June 01, 2018, “Your Daily Pharma Scoop: Recent IPO And Offerings Review” on May 31, 2018, “Mid-Morning Market Update: Markets Open Higher; Abercrombie & Fitch Beats Q1 Expectations” with a publish date: June 01, 2018, “SELLAS Life Sciences Announces Proposed Public Offering of Common Stock” and the last “54 Biggest Movers From Yesterday” with publication date: June 27, 2018.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications.The company has $21.56 million market cap. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia.Currently it has negative earnings. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: